Replies to post #55742 on US Stem Cell Inc (USRM)

[andrewd173]

The revenue stream for the rest of the world is pretty sibstantial in its own right. and also international trials are much cheaper to run.

I don't see this happening, but if RMAT was declined, there would be a hard oversell then slow rise based on organic revenue and/or completion points on a normal phase 3.